Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke prevention in atrial fibrillation III study

JAMA

Volumn 279, Issue 16, 1998, Pages 1273-1277

  McBride, Ruth ^a  

^a SPAF Statistical Coordinating Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 0032557174     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.16.1273     Document Type: Article

References (25)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;2:983-988.
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449-1457.
4. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med. 1997;157:1237-1240.
5. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994; 343:687-691.
6. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over 3 decades. N Engl J Med. 1987;317:669-674.
7. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
8. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features in patients at risk. Ann Intern Med. 1992;116:1-5.
9. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features in patients at risk. Ann Intern Med. 1992;116:6-12.
10. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis. 1995;5:147-157.
11. Van Latum JC, Koudstaal PJ, Venables GS, Van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with non-rheumatic atrial fibrillation. Stroke. 1995;26: 801-806.
12. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III Study: rationale, design and patient features. J Stroke Cerebrovasc Dis. 1997;5:341-353.
13. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
14. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
15. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993;43: 32-36.
16. Bamford JM, Sandercock PAG, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989; 20:828.
17. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol. 1989;42:711-718.
18. Kronmal RA, Hart RG, Manolio T, et al. Aspirin use and incident stroke in the Cardiovascular Health Study. Stroke. In press.
19. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
20. Hart RG. Management of atrial fibrillation. In: Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B, eds. Primer on Cerebrovascular Diseases. New York, NY: Academic Press; 1997:786-791.
21. Lin HJ, Wolf PA, Kelly-Hays M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;7:1760-1764.
22. Flegel KM, Harley J. Risk factors for stroke and other embolie events in patients with nonrheumatic atrial fibrillation. Stroke. 1989;20:1000-1004.
23. Man-Son-Hing M, Laupacis A, O'Connor A, Wells G. Warfarin for atrial fibrillation: the patient perspective. Arch Intern Med. 1996;156:1841-1848.
24. Flegel KM, Hutchinson TA, Gromme PA, Tousignant P. Factors relevant to preventing embolic stroke in patients with nonrheumatic atrial fibrillation. J Clin Epidemiol. 1991;44:551-560.
25. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med. 1996;156:409-416.